TRISYNTEC, Inc.

About TRISYNTEC, Inc.

TRISYNTEC represents an industry-changing, first-in-class diagnostic and therapeutic device that will redefine and transform the global chronic respiratory disease (CRD) patient care market. Our wearable, multifaceted, "Deep Wave" stimulation technology allows the body to breathe, rebalance itself, and regenerate by activating its normal physiological mechanisms. Current granted patents are in China, Japan, S. Korea, the US, the EU, Australia, and Canada. As we enter the APAC region in 3Q, we will add India, Africa, and the Middle East. Its Gen I and Gen II chronic respiratory disease-oriented models stimulate the diaphragm and the autonomic nervous system, thereby creating an ecosystem of diversified chronic respiratory disease patient treatment digital health assets that leverage real-world data and evidence to deliver high-efficacy treatments. Prior trials demonstrated a 43% increase in breathing capability. Recent tests revealed the following "Deep Wave" therapeutic impacts: > Data shows we are reducing the biological age by up to 15 years. This is understandable due to the improvement in heart rate variability, and better breathing, plus improved deep sleep phase. > We also have recent data showing that the improvement in heart rate variability translates to a 50% reduction in heart attacks. In conclusion to our 3Q late-stage India clinical trial, an APAC pharma licensing agreement is pending for China and Japan to begin in early 1Q '27.